15 completed, 5 unknown, 1 not yet recruiting, 1 recruiting. 11 Phase 3, 4 Phase 2, 3 Not applicable, 1 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 10, Unknown 1 |
| Phase 2 | 4 | Unknown 2, Completed 1, Withdrawn 1 |
| Not applicable | 3 | Unknown 2, Completed 1 |
| Early Phase 1 | 1 | Not yet recruiting 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 4 | 1 | Completed 1 |
Follow Biguanides: new trials by email Literature Review of Biguanides trials Research Report on Biguanides
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of a Polyhexanide Biguanide-Based Gel in the Prevention of Biofilm Formation in Pressure Ulcers To determine the efficacy of a gel containing polyhexanide and biguanide, alone or in combination with alginate with or without silver, in preventing biofilm in PU, in terms of healing at 4 weeks - Pressure Ulcers, Pressure Ulcers Stage III | Early Phase 1 | Not yet recruiting | Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana | 140 | 2026-01-30 | 2026-02-10 |
| A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs Exenatide, Non-GLP-1 RA based glucose lowering drugs - Pancreatic Cancer | Recruiting | AstraZeneca | 24000 | 2024-09-30 | 2026-09-24 | |
| TEsting METformin Against Cognitive Decline in HD Metformin, Placebo - Huntington Disease | Phase 3 | Completed | Instituto de Investigacion Sanitaria La Fe | 60 | 2022-04-11 | 2025-09-25 |
| Alter-G Training on Gait and Balance in Diabetic Neuropathy Patients Group- A (100% weight-bearing; n=14), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks., Group- B (70% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks., Group- C (50% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks. - Diabetic Peripheral Neuropathy | Not applicable | Completed | Umm Al-Qura University | 68 | 2022-01-02 | 2022-10-04 |
| Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression Metformin, Empagliflozin, Control - Renal Insufficiency, Chronic | Phase 2 / Phase 3 | Completed | Tanta University | 118 | 2022-01-01 | 2025-08-14 |
| LIpitor and biGuanide to Androgen Delay Trial Metformin, Atorvastatin, Placebo (corresponding to metformin) - Prostate Cancer | Phase 2 | Withdrawn | University Health Network, Toronto | 2021-12-01 | 2021-04-19 | |
| ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT Biguanide, DPP4 inhibitors, SGLT2 inhibitors - Abdominal Obesity, Type 2 Diabetes | Not applicable | Unknown | Metabolic Research Unit | 30 | 2021-08-01 | 2021-09-09 |
| Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg - Impaired Glucose Tolerance, Insulin Sensitivity | Phase 2 | Unknown | Oslo University Hospital | 64 | 2021-02-10 | 2021-04-08 |
| Dapagliflozin Effect in Cognitive Impairment in Stroke Trial Dapagliflozin 10mg Tab, Statins (Cardiovascular Agents), Platelet Antiaggregant - Stroke, Ischemic, Mild Cognitive Impairment | Phase 2 / Phase 3 | Unknown | Jaime Daniel Mondragon | 270 | 2020-08-01 | 2022-10-04 |
| Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects Bydureon, Humulin kwickpen, Metformin - Atherosclerosis, Diabetes | Phase 4 | Completed | Karolinska Institutet | 38 | 2015-12-01 | 2023-04-20 |
| Treatment of Recurrent Brain Tumors: Metabolic Manipulation Combined With Radiotherapy Partial brain re-irradiation., Metformin, low carbohydrate diet - Brain Neoplasms | Phase 1 | Unknown | Sheba Medical Center | 18 | 2014-06-01 | 2017-10-27 |
| Incretin-based Drugs and the Risk of Heart Failure DPP-4 inhibitors, GLP-1 analogs, Insulins - Type 2 Diabetes Mellitus | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 1499650 | 2014-03-01 | 2016-04-19 | |
| Incretin-based Drugs and Acute Pancreatitis DPP-4 inhibitors, GLP-1 analogs, Insulins - Diabetes Mellitus, Type 2 | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 1417914 | 2014-03-01 | 2016-11-03 | |
| Incretin-based Drugs and Pancreatic Cancer DPP-4 inhibitors, GLP-1 analogs, Sulfonylureas - Diabetes Mellitus, Type 2 | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 886172 | 2014-03-01 | 2016-03-14 | |
| Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes lixisenatide AVE0010, biguanide, TZD - Type 2 Diabetes Mellitus | Phase 3 | Completed | Sanofi | 294 | 2013-09-01 | 2015-08-04 |
| A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment Insulin Peglispro, Insulin Glargine, Oral Antihyperglycemic Medications (OAMs) - Type 2 Diabetes Mellitus | Phase 3 | Completed | Eli Lilly and Company | 388 | 2013-07-01 | 2019-03-15 |
| A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus Albiglutide, Sulfonylurea, Biguanide - Diabetes Mellitus | Phase 3 | Completed | GlaxoSmithKline | 374 | 2013-02-23 | 2017-05-03 |
| A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus LY2189265, Insulin glargine, Sulfonylureas (SU) - Type 2 Diabetes Mellitus | Phase 3 | Completed | Eli Lilly and Company | 361 | 2012-04-01 | 2014-10-20 |
| A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus LY2189265, Sulfonylureas (SU), Biguanides (BG) - Type 2 Diabetes Mellitus | Phase 3 | Completed | Eli Lilly and Company | 394 | 2011-11-01 | 2015-01-29 |
| Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes teneligliptin, glinide, biguanide - Type 2 Diabetes Mellitus | Phase 3 | Completed | Tanabe Pharma Corporation | 462 | 2011-02-01 | 2026-01-02 |
Showing 20 of 23. Sign in to see all of them.
Diabetes Mellitus, Type 2 (11) · Insulin Resistance (5) · Diabetes Mellitus (3) · Pancreatic Neoplasms (2) · Astrocytoma (1) · Atherosclerosis (1) · Brain Neoplasms (1) · Cardiovascular Diseases (1) · Cognitive Dysfunction (1) · Coronary Disease (1) · Dementia, Vascular (1) · Diabetic Nephropathies (1) · Diabetic Neuropathies (1) · Diabetic Retinopathy (1) · Glioblastoma (1)
Canadian Network for Observational Drug Effect Studies, CNODES (3) · Eli Lilly and Company (3) · AstraZeneca (1) · Federico II University (1) · Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (1) · GlaxoSmithKline (1) · Instituto de Investigacion Sanitaria La Fe (1) · Jaime Daniel Mondragon (1) · Karolinska Institutet (1) · Metabolic Research Unit (1) · Oslo University Hospital (1) · Sanofi (1) · Sheba Medical Center (1) · Shiga University (1) · Tanabe Pharma Corporation (1)
Japan (7) · Canada (4) · Mexico (2) · Norway (2) · Spain (2) · Sweden (2) · Denmark (1) · Egypt (1) · Finland (1) · France (1) · Israel (1) · Saudi Arabia (1) · South Korea (1) · Taiwan (1) · United Kingdom (1)
Pierre Ernst, MD, MSc (3) · Annamaria Colao, MD PhD (1) · Ashraf Abdelaal (1) · Atsunori Kashiwagi, PhD. (1) · Bernard Chaitman, MD (1) · Burton Sobel (1) · Fabian Hoti, PhD (1) · Kazuoki Kondo, MD (1)
PMID 15353407, PMID 20204386, PMID 20452396, PMID 20630463, PMID 20671408, PMID 21444887, PMID 21473976, PMID 21742107, PMID 21768545, PMID 21835316, PMID 21846339, PMID 21911782, PMID 22390929, PMID 22496082, PMID 23008442, PMID 23040716, PMID 23241323, PMID 23343509, PMID 23410541, PMID 23500245, PMID 23500281, PMID 23735723, PMID 23757426, PMID 23857320, PMID 23910429, PMID 24178969, PMID 25861982, PMID 25966620, PMID 26267622, PMID 26271057, PMID 26853953, PMID 26888382, PMID 27007958, PMID 27289411, PMID 27479930, PMID 27852119, PMID 28095900, PMID 28126156, PMID 28606095, PMID 28903941, PMID 28950419, PMID 29016744, PMID 29371333, PMID 29446769, PMID 29573529, PMID 30286920, PMID 31236801, PMID 31248555, PMID 31535829, PMID 31590967
U01HL061744 (1), U01HL061746 (1), U01HL061748 (1), U01HL063804 (1)